Alchemab Therapeutics
Developing antibody medicines from naturally resilient individuals for neurodegenerative diseases, cancer, and infectious diseases.
Website: https://www.alchemab.com/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | Alchemab Therapeutics |
| Tagline | Developing antibody medicines from naturally resilient individuals for neurodegenerative diseases, cancer, and infectious diseases [alchemab.com] |
| Headquarters | Cambridge, UK [Crunchbase] |
| Founded | 2019 [Crunchbase] |
| Stage | Series A [Cambridge Independent, July 2026] |
| Business model | B2B |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (2), Jane Osbourn and Uri Laserson [Cambridge Independent, July 2026] [Crunchbase] |
| Funding label | $100M+ |
| Total disclosed funding | Approximately $118,000,000, based on $82,000,000 Series A, $2,000,000 Innovate UK grant, and $34,000,000 Series A extension (estimated) [Alchemab, April 2021] [Alchemab, December 2022] [Cambridge Independent, July 2026] |
Links
Open sources
- Website: https://www.alchemab.com/
- LinkedIn: https://uk.linkedin.com/company/alchemab-therapeutics-ltd
What an Investor Needs First
PUBLIC Alchemab Therapeutics is a Cambridge-based biotech developing antibody medicines from people who appear naturally resilient to serious disease, and it merits investor attention now because its lead disclosed program, ATLX-1282, entered a first-in-human Phase 1 study in September 2025 after a licensing agreement with Eli Lilly in May 2025, moving the story from platform promise toward clinical and partnering validation [alchemab.com, September 2025]. Founded in 2019 by Jane Osbourn and Uri Laserson, the company has built its thesis around what it calls the Resiliome, a discovery platform designed to identify protective antibodies in resilient individuals, map their biological targets, and convert those findings into therapeutics across neurodegenerative disease, cancer, and infectious disease [alchemab.com] [Cambridge Independent, July 2026].
The differentiation claim rests less on a single antibody asset than on the upstream discovery method: Alchemab says it combines deep sequencing, AI-based analysis, and laboratory validation to find naturally occurring protective antibodies that conventional target-first workflows may miss [European Biotechnology Magazine] [Cambridge Independent]. That is still best read as a company-framed advantage rather than independently settled evidence, but the Lilly transaction and the transition of ATLX-1282 into the clinic give the platform a more concrete external signal than many discovery-stage peers can show [alchemab.com, September 2025] [Cambridge Independent, July 2026].
The team is one reason the company has attracted serious specialist capital. Osbourn, now CEO after succeeding Young Kwon in September 2024, previously held senior R&D leadership roles at MedImmune, AstraZeneca's biologics arm, while Laserson is a scientific founder with prior company-building experience and external recognition including Forbes' 2012 30 Under 30 list [alchemab.com, September 2024] [Citeline Insights] [MedCity News] [Forbes].
On capital formation, the company has disclosed an unusually large Series A base for a European biotech of its age: £60 million in April 2021, a £1.7 million Innovate UK grant in December 2022, and a £25 million Series A extension reported in July 2026 that brought the total Series A to £109 million, with investors including SV Health Investors, Dementia Discovery Fund, RA Capital, DCVC Bio, Eli Lilly, Lightstone Ventures, Ono Venture Investment, Camford Partners, and the British Business Bank [Alchemab, April 2021] [Alchemab, December 2022] [Cambridge Independent, July 2026]. The commercial model appears to be the standard biotech mix of internal pipeline creation and value inflection through licensing or broader biopharma partnerships, with Lilly providing the clearest disclosed example so far [alchemab.com, September 2025].
Over the next 12 to 18 months, the main public markers to watch are early read-through from the Phase 1 progression of ATLX-1282, any additional licensing or co-development activity that tests whether the platform is repeatable beyond a single asset, and evidence that the expanding antibody sequence database is translating into a broader clinical pipeline rather than remaining a research-scale advantage claim [alchemab.com, September 2025] [LinkedIn] [Cambridge Independent, July 2026].
Claim stands unchecked -- This section mixes independently corroborated funding and leadership facts with company-led product, platform, and pipeline claims that remain primarily supported by Alchemab materials, plus limited independent corroboration from Cambridge Independent and sector trade coverage.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | $100M+ total disclosed, approximately $118,000,000 [Alchemab, April 2021] [Alchemab, December 2022] [Cambridge Independent, July 2026] |
Inside the Company
PUBLIC
Alchemab Therapeutics presents as a Cambridge, UK biotechnology company built around a specific discovery thesis: start with people who appear unusually resilient to severe disease, then identify antibodies that may explain that resilience and develop them into medicines [Crunchbase] [alchemab.com]. Public company profiles and the company website place its founding in 2019, with Jane Osbourn and Uri Laserson identified among the founders and scientific founders [Crunchbase] [alchemab.com]. The available public materials do not add a state filing or legal incorporation detail beyond the operating name used on the website and company profiles.
The visible milestones are relatively clear even if the chronology remains company-led. Alchemab announced a £60 million Series A financing in April 2021 to advance its antibody discovery platform and pipeline [alchemab.com, April 2021]. In December 2022, it announced a £1.7 million Innovate UK Biomedical Catalyst grant [alchemab.com, December 2022]. In September 2024, the company said co-founder Jane Osbourn succeeded Young Kwon as chief executive officer after previously serving as chief scientific officer [alchemab.com, September 2024]. In September 2025, Alchemab announced that its lead disclosed asset, ATLX-1282, had entered a first-in-human Phase 1 study [alchemab.com, September 2025].
The company has continued to add capital against that platform story. Crunchbase identifies Alchemab as a venture-backed therapeutics company in Cambridge, and company materials describe a focus spanning neurodegenerative disease, cancer, and infectious disease [Crunchbase] [alchemab.com]. The broad outline is credible on public record: a 2019-founded UK biotech, financed early at scale, now with at least one disclosed clinical-stage asset and a platform narrative that remains central to the company identity [Crunchbase] [alchemab.com, September 2025].
Partially corroborated -- Core company identity and founding year are corroborated by Crunchbase and the company website, but milestone chronology in this section relies materially on company announcements [Crunchbase] [alchemab.com, April 2021] [alchemab.com, December 2022] [alchemab.com, September 2024] [alchemab.com, September 2025].
Under the Hood
Reported and inferred
Alchemab is building antibody medicines by starting with people who appear unusually resistant to severe disease, then looking for protective immune signals that can be developed into therapeutics [Alchemab] [LinkedIn]. In public materials, the company calls this approach the Resiliome, or "resiliomics," and describes it as a process for identifying naturally occurring antibodies in resilient individuals, finding the biological targets those antibodies act on, and advancing selected candidates into drug programs [Alchemab] [Cambridge Independent, July 2026] [European Biotechnology Magazine]. The disease areas described across company and press sources are neurodegeneration, cancer, and infectious disease, although the strongest public evidence sits with neurodegeneration and oncology rather than a broader commercial footprint [Alchemab] [PharmaTimes].
The technical workflow described in source material is consistent, if still light on disclosed operating detail. Alchemab says the platform combines deep sequencing, AI-based analysis, and laboratory validation to identify antibodies and targets that may have therapeutic value [European Biotechnology Magazine] [Cambridge Independent]. Company-linked sources also indicate the platform is being scaled through a proprietary antibody dataset that was reported at 500 million sequences and is intended to grow beyond one billion sequences [European Biotechnology Magazine] [LinkedIn]. Those figures matter less as raw volume than as a signal of ambition: in antibody discovery, a large sequence corpus can strengthen hit-finding and target-mapping, but public sources here do not yet quantify conversion rates, success probabilities, or program-level productivity.
The clearest proof that the platform is producing assets is ATLX-1282, which Alchemab announced had entered a first-in-human Phase 1 study in September 2025, with the company also stating that Eli Lilly licensed the program under an exclusive global agreement in May 2025 [Alchemab, September 2025]. That does not by itself validate the full platform across indications, but it does move the story beyond platform rhetoric and into clinical and partnering evidence. There are also signs of meaningful computational biology depth, although any specific stack description would be speculative; the only public clue is hiring for roles such as principal deep learning researcher and principal bioinformatician, which supports the inference that machine learning and large-scale biological data analysis are central to the discovery engine (inferred from job postings) [DCVC Job Board, Retrieved 2026].
Partially corroborated -- Product architecture and lead-program status rely heavily on company materials, with partial corroboration from Cambridge Independent and other trade coverage.
Market Research
PUBLIC
The market matters now because neurodegenerative drug development remains one of biopharma's least solved, and investors are funding discovery platforms that can produce differentiated antibody assets rather than single-asset companies [PharmaTimes] [Cambridge Independent, July 2026].
The constraint in this case is straightforward: the available source set does not include a named third-party TAM, SAM, or SOM estimate for Alchemab's target markets, so any sizing exercise has to stay anchored to analogous public markets rather than present a false precision. Public materials place Alchemab across neurodegenerative diseases, cancer, and infectious diseases, with the lead disclosed program, ATLX-1282, in ALS and related neurodegenerative diseases [alchemab.com] [Excedr]. That positioning implies exposure to large therapeutic end markets, but the investable question is narrower: whether a resilience-based antibody discovery engine can repeatedly generate assets that attract licensing demand from large pharmaceutical buyers [alchemab.com, September 2025] [Cambridge Independent, July 2026].
Demand drivers in the cited record come through more clearly than market size. The company's stated focus on hard-to-treat neurodegenerative diseases and cancers aligns with disease areas where unmet need remains high and conventional target-first discovery has often produced uneven clinical outcomes [PharmaTimes]. The Lilly licensing agreement for ATLX-1282, disclosed by the company in connection with the asset's Phase 1 start, is also a useful signal that external pharma buyers will pay attention when a platform yields a clinically advancing program, even if the economics of that transaction were not disclosed in the sources reviewed [alchemab.com, September 2025].
The adjacent markets are also relevant because Alchemab is not selling into a single category. It sits at the intersection of antibody therapeutics, AI-assisted drug discovery, and human-omics driven target identification, according to company and trade descriptions of the Resiliome platform's use of deep sequencing, algorithmic analysis, and laboratory validation [European Biotechnology Magazine] [Synapse] [Cambridge Independent]. That creates multiple substitute paths for partners, including conventional antibody discovery, broader computational drug discovery platforms, and target-discovery companies built around human biological data rather than resilience cohorts [European Biotechnology Magazine] [PharmaTimes].
Regulatory and macro forces cut both ways. On the supportive side, capital has remained available for differentiated clinical-stage biotech stories, and Alchemab's Series A extension led by the British Business Bank suggests continued public-private support for UK life sciences infrastructure and translational research [Cambridge Independent, July 2026] [EU-Startups, July 2026]. The counterweight is familiar to any therapeutics investor: long development timelines, binary clinical readouts, and a funding market that tends to reward platform companies only when they convert discovery claims into human data or partner validation [alchemab.com, September 2025] [Cambridge Independent, July 2026].
| Cited market-relevant claim | Relevance to Alchemab | Source |
|---|---|---|
| Alchemab focuses on neurodegenerative diseases, cancer, and infectious diseases | Indicates exposure to three large therapeutic areas rather than a single niche | [alchemab.com] |
| ATLX-1282 entered a first-in-human Phase 1 study in September 2025 | Shows progression from platform story toward clinical market validation | [alchemab.com, September 2025] |
| Eli Lilly licensed ATLX-1282 under an exclusive global licensing agreement in May 2025, according to the company's September 2025 announcement | Suggests demand from large pharma for assets emerging from the platform | [alchemab.com, September 2025] |
| The Series A extension brought total Series A funding to £109 million | Implies investors see a large enough commercial opportunity to continue backing the platform | [Cambridge Independent, July 2026] |
The table underscores a practical point: the public record supports a market-opportunity argument through partner behavior and financing depth more than through formal sizing data. That is weaker than having a clean third-party TAM model, but it is still informative for a platform biotech whose first proof of market often arrives via licensing rather than product sales.
Partially corroborated -- Section relies on one independent publisher for funding context and multiple company or trade sources for market positioning; no third-party TAM/SAM/SOM study was available in the cited materials.
Competition and Substitutes
Competitive position
MIXED Alchemab is positioned less as a conventional single-asset biotech and more as a discovery platform company that tries to start from naturally resilient human biology, which places it at the intersection of antibody therapeutics, AI-assisted target discovery, and biopharma partnering rather than in a neatly bounded peer set [Alchemab, April 2021] [Cambridge Independent, July 2026] [European Biotechnology Magazine] [Synapse].
The competitive map is therefore fragmented. On one side sit large incumbent biopharma groups with the balance sheet, clinical infrastructure, and commercial reach to internalize antibody discovery and development, a category that matters here because Eli Lilly has already licensed ATLX-1282 under an exclusive global agreement, according to Alchemab's September 2025 announcement [Alchemab, September 2025]. A third bucket is adjacent substitute approaches in neurodegeneration and oncology, where competitors may win not by finding similar antibodies but by advancing small molecules, cell therapies, gene therapies, or in-licensed biologics through the clinic faster.
Alchemab's current edge, on the public evidence, appears to rest on a combination of proprietary biological data, a differentiated discovery thesis, and senior antibody-development talent. The company says its Resiliome platform identifies protective antibodies from resilient individuals and maps those antibodies to therapeutic targets, and later funding commentary indicates management aims to expand its proprietary database to more than one billion sequences, up from 500 million cited elsewhere [Alchemab] [European Biotechnology Magazine] [LinkedIn]. That can be durable if the dataset is hard to replicate and if the signal improves with scale, but it is also perishable in the usual platform-biotech way: the edge matters only if it repeatedly produces assets that survive translational risk, and today the lead publicly disclosed proof point is one Phase 1 program, ATLX-1282 [Alchemab, September 2025].
The company is most exposed where scale advantages sit outside its control. Lilly is the clearest named comparator and partner at once: its specific advantage is downstream, with greater clinical-development capacity, regulatory experience, and global commercialization infrastructure than Alchemab could plausibly build as a Series A-stage biotech [Alchemab, September 2025] [Cambridge Independent, July 2026]. That does not make Lilly a head-to-head competitor in every context, but it does define the ceiling of what Alchemab can own alone. If value accrues mainly at the discovery and early-clinical stage, Alchemab can capture meaningful economics through licensing. If value shifts toward late-stage execution and market access, larger pharma will hold the stronger channel.
The most plausible 18-month scenario is that competitive standing is determined by external validation rather than breadth of pipeline headlines. Winner if X: Eli Lilly, if ATLX-1282 generates enough early clinical or translational signal to justify deeper internal commitment, because Lilly already controls the licensed program and is positioned to compound any success through development speed and partnering credibility [Alchemab, September 2025]. Loser if Y: Alchemab, if the Resiliome platform does not produce a second visible validation event, whether another licensing deal, a new clinical entry, or independent evidence that the discovery engine generalizes beyond a single lead, because public claims about database scale and algorithmic differentiation would then remain more suggestive than proven [Cambridge Independent, July 2026] [European Biotechnology Magazine] [Alchemab, September 2025].
Opportunity
Upside case
Open sources If Alchemab executes, the prize is not a single successful drug but a repeatable engine for finding human-derived antibody medicines in diseases where conventional target-first discovery has struggled [Alchemab, April 2021] [Cambridge Independent, July 2026].
The headline opportunity is to become a category-defining antibody discovery platform built around naturally resilient individuals, then convert that platform advantage into both internal pipeline value and external licensing value [alchemab.com] [Cambridge Independent, July 2026]. That outcome is reachable, rather than purely aspirational, because there is already some evidence of translation across the chain that matters in biotech: the company raised an £60 million Series A in 2021, later extended the round to £109 million in total, and advanced ATLX-1282 into a first-in-human Phase 1 study in September 2025 [Alchemab, April 2021] [Finsmes, April 2021] [Cambridge Independent, July 2026] [alchemab.com, September 2025]. The May 2025 exclusive global licensing agreement with Eli Lilly for ATLX-1282 is the clearest public signal that a large pharmaceutical counterparty viewed at least one output of the platform as commercially and scientifically credible [alchemab.com, September 2025].
That matters because platform biotechs tend to create outsized value only when the discovery method starts producing multiple monetization paths at once: partnered assets, retained economics on internal programs, and a growing data advantage that improves subsequent hit-finding [European Biotechnology Magazine] [Cambridge Independent, July 2026]. Alchemab's public case rests on that logic. The company says the new funding will expand its proprietary antibody database beyond one billion sequences, up from 500 million, while also broadening the clinical pipeline [LinkedIn] [European Biotechnology Magazine]. If those claims hold in practice, the business starts to look less like a single-asset biotech and more like a platform with accumulating search advantages.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform validation through pharma partnering | Alchemab becomes a repeat partner to large drugmakers that want access to its antibody discovery engine, generating milestone-bearing licensing deals across neurodegeneration, oncology, and infectious disease | A second publicly disclosed licensing or collaboration agreement after the Lilly transaction | Lilly already licensed ATLX-1282 under an exclusive global agreement, which suggests at least one major pharma found the platform output worth externalizing into a global deal [alchemab.com, September 2025] |
| Transition from platform story to clinical biotech | ATLX-1282 or a follow-on program produces encouraging early human data, allowing Alchemab to retain more downstream value on selected assets while partnering others | Readthrough from the Phase 1 initiation announced in September 2025 | The company has already moved one disclosed asset into first-in-human study, which is a material step beyond discovery-stage positioning [alchemab.com, September 2025] |
| Data moat compounds into pipeline breadth | The Resiliome dataset grows past one billion antibody sequences and improves target identification, increasing the odds of generating multiple candidates from the same discovery stack | Deployment of the 2026 financing into database expansion and pipeline growth | Management-linked and company-linked sources explicitly tied the new funding to expanding the proprietary antibody database and accelerating next-generation therapeutic discovery [LinkedIn] [European Biotechnology Magazine] [Cambridge Independent, July 2026] |
The compounding mechanism here is a data-and-validation flywheel, though it is still early and mostly evidenced by company and partner signals rather than independent operating metrics [alchemab.com] [Cambridge Independent, July 2026]. Alchemab's model starts with identifying people who appear unusually resilient to serious disease, sequencing for protective antibodies, using AI-based analysis to identify relevant antibodies and targets, and then validating those findings in the lab before advancing candidates into development [LinkedIn] [European Biotechnology Magazine] [Synapse]. Each successful output should, in principle, improve three things at once: the proprietary sequence corpus, the company's understanding of which biological patterns translate into therapeutic hypotheses, and its credibility with pharma partners that can fund later-stage development [alchemab.com] [Cambridge Independent, July 2026]. The Lilly license and the Phase 1 entry of ATLX-1282 suggest that the first turn of that flywheel may already be underway, even if the public record does not yet establish repeatability across several partnered assets [alchemab.com, September 2025].
The size of the win is best framed as platform optionality rather than a point estimate. No public valuation was disclosed in the reviewed sources, and no source set here provides a clean public comparable market cap or transaction multiple that can be responsibly ported over [Cambridge Independent, July 2026]. Still, if the pharma-partnering scenario or the transition-to-clinical-biotech scenario plays out, the business could plausibly graduate from a venture-backed UK platform biotech into a multi-asset company with strategic value well beyond the £109 million Series A base, particularly because one asset has already been licensed to Lilly and the company has continued to attract specialist life sciences capital including SV Health Investors, RA Capital, DCVC Bio, Lightstone Ventures, Ono Venture Investment, and the British Business Bank [Cambridge Independent, July 2026]. That is a large outcome set by private biotech standards, even if the public evidence is not yet strong enough to anchor a precise worth figure without drifting into speculation.
Partially corroborated -- Section relies on a mix of independent reporting and company disclosures. Funding history and investor roster are corroborated by independent coverage, while platform mechanics, database scale claims, and pipeline details are partly or primarily company-sourced.
Sources
Open sources
[alchemab.com, April 2021] Alchemab raises £60 million ($82 million) in Series A financing | https://www.alchemab.com/news/
[alchemab.com, December 2022] Innovate UK Biomedical Catalyst grant announcement | https://www.alchemab.com/news/
[alchemab.com, September 2024] Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer | https://www.alchemab.com/news/
[alchemab.com, September 2025] Alchemab announces initiation of Phase 1 first-in-human study of ATLX-1282 | https://www.alchemab.com/news/
[alchemab.com] Alchemab Therapeutics | https://www.alchemab.com/
[Cambridge Independent, July 2026] £25m Series A boost is a huge vote of suppoprt for Alchemab’s resiliomics | https://www.cambridgeindependent.co.uk/business/25m-series-a-boost-is-a-huge-vote-of-suppoprt-for-alchemab-9474365
[Crunchbase] Alchemab Therapeutics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/alchemab-therapeutics
[DCVC Job Board, Retrieved 2026] Alchemab Therapeutics | DCVC Job Board | https://jobs.dcvc.com/companies/alchemab-therapeutics
[EU-Startups, July 2026] Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet | https://www.eu-startups.com/2026/07/londons-alchemab-therapeutics-secures-e29-3-million-as-british-business-bank-makes-its-largest-life-sciences-investment-yet/
[Finsmes, April 2021] Alchemab Raises £60M in Series A Financing | https://www.finsmes.com/2021/04/alchemab-raises-60m-in-series-a-financing.html
[LinkedIn] Alchemab Therapeutics Ltd | LinkedIn | https://uk.linkedin.com/company/alchemab-therapeutics-ltd
Articles about Alchemab Therapeutics
- Alchemab Therapeutics Is Reading the Immune System Backwards — The Cambridge biotech, led by an AstraZeneca veteran, is using its Resiliome platform to find protective antibodies in people who stay healthy against the odds.